« Back to Record
Citation APA

Piccart-Gebhart, M., Hortobagyi, G. N., Campone, M., Pritchard, K., Lebrun, F., Ito, Y., Noguchi, S., Perez, A., Rugo, H., Deleu, I., Burris, H. A., Provencher, L., Neven, P., Gnant, M., Shtivelband, M., Wu, C., Fan, J., Feng, W., Taran, T., & Baselga, J. (2014). Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. Annals of oncology, 25(12), 2357-2362. doi:10.1093/annonc/mdu456


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/200276

Piccart-Gebhart, M., Hortobagyi, G. N., Campone, M., Pritchard, K., Lebrun, F., Ito, Y., Noguchi, S., Perez, A., Rugo, H., Deleu, I., Burris, H. A., Provencher, L., Neven, P., Gnant, M., Shtivelband, M., Wu, C., Fan, J., Feng, W., Taran, T., & Baselga, J. (2014). Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. Annals of oncology, 25(12), 2357-2362. doi:10.1093/annonc/mdu456